Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing protein 3 (WDR3) is a nuclear protein characterized by 10 WD repeats—structural motifs of approximately 30–40 amino acids ending in a tryptophan-aspartic acid (W-D) pair[1][3][4][5]. As a member of the WD repeat protein family, WDR3 acts as a scaffold or platform for protein-protein interactions in crucial complexes, particularly in the assembly of the small subunit (SSU) processome involved in ribosome biogenesis[1][3][4][5]. Its core cellular roles include rRNA processing, control of the cell cycle, and participation in functions such as signal transduction and gene regulation[1][3][4]. Although not a classic therapeutic target such as a receptor or enzyme, WDR3 has been described in cancer biology, where it integrates ribosomal biogenesis with the p53 pathway influencing cancer cell proliferation[7]. There are no known direct drugs, biomarkers, or established safety concerns for this molecule as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing protein 3 (WDR3).